Corporate Profile
We are a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Leveraging recent research implicating microglial dysfunction in neurodegenerative diseases, we utilize a precision medicine approach to develop a pipeline of therapeutic candidates that we believe will activate and restore microglial function.
Stock Quote
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
May 08, 2024
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
May 07, 2024
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
Apr 17, 2024
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
Events & Presentations
May 14, 2024 | 11:30 AM EDT